Healthcare
Inventiva S.A.(IVA)
Live Price
Offline$3.57
+1.13% today
1Y Change
+16.61%
Window
Jun 25, 2025 โ Jun 16, 2026
- Market Cap
- $600.00M
- Revenue Growth
- -51.3%
- EPS Growth
- +48.6%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 25, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Inventiva S.A. (IVA) is a Healthcare stock with a market cap of $600.00M and listed on NASDAQ. The stock last traded around $3.57 and up 16.6% across the available one-year price window (Jun 25, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of -51.3%, EPS growth of +48.6%, a dividend yield of 0.0%. What stands out right now is revenue -51.3%, EPS +48.6%, free cash flow -17.3% with operating margin -3037.3% and ROIC -66.2%. Valuation already assumes a fairly strong business story at price/sales 133.7. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines IVA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-51.3% vs +7.6% peer median
Operating Margin
Below sector median
-3037.3% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Mar 30, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -51.3% and EPS is at +48.6%, with operating margin around -3037.3%.
The next real check-in already has a date
The next earnings event is scheduled for Sep 25, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.2% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 30, 2026 | โ | +1.3% | -2.6% | -8.6% |
2025 Sep 25, 2025 | -361.7% | +0.7% | +4.8% | -2.3% |
2025 May 23, 2025 | -472.9% | +3.1% | -2.9% | +10.4% |
Benchmark Edge
IVA vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
IVA
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
IVA Max Drawdown
-49.93%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for IVA and SPY.
Company Overview
Inventiva S.A.
NASDAQ Global Market
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
- Leadership
- Andrew Obenshain
- IPO Date
- Jul 10, 2020
- Employees
- 114
- Street Address
- 50 rue de Dijon
- Mailing
- Daix, 21121
- Region
- Daix, FR
- Reporting Currency
- USD
- Investor Line
- 33 3 80 44 75 00
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 133.7
- Price/Book
- โ
Growth
- Revenue
- -51.3%
- EPS
- +48.6%
- Free Cash Flow
- -17.3%
Profitability
- Gross Margin
- 35.1%
- Operating Margin
- -3037.3%
- Net Margin
- -7899.6%
- ROE
- 1870.4%
- ROIC
- -66.2%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 3.16
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.